This is the SEO and AEO layer over the raw /coa/ archive. Three Janoshik-tested retatrutide batches back the four currently shipping SKUs: RETP002 (30mg pen, 99.262% HPLC), RET-20-C-2604-001 (20mg pen, 99.841% HPLC), and RET-20-V-2604-001 (vial line, 99.741% HPLC, with the additional heavy metals, residual TFA, and bacterial endotoxin panels on top of HPLC). Each batch has its own per-SKU summary page below.
Published Batches
- Highest purity
- 99.841% HPLC — 20mg Pen, batch
RET-20-C-2604-001 - Tested batches
- 3 batches covering 4 SKUs
- Testing lab
- Janoshik Analytical — EU, independent
- Panels published
- HPLC purity, assay, residual TFA, heavy metals (As, Cd, Pb, Hg), bacterial endotoxin (LAL)
- Newest report
- 23 April 2026 —
RET-20-C-2604-001
Per-SKU Reports
The Retatrutide 10mg Pen ships under a per-order COA model — see the product page at /retatrutide-10mg-pen for current batch information. It has no fixed lab-results page yet because no batch has been published to the public archive.
Methodology
Why Janoshik. Every published Remy Peptides batch is sent to Janoshik Analytical, an independent third-party peptide testing lab based in the EU. Janoshik is the lab most frequently cited by research-peptide suppliers because every certificate carries a task number and verification key that lets any third party cross-check the report against the Janoshik server. Remy does not host or edit the reports — the PDFs and images are reproduced exactly as Janoshik issued them.
What HPLC measures, and doesn't. Reverse-phase HPLC on a C18 stationary phase separates the parent peptide fraction from peptide-related impurities (truncated sequences, deletion variants, synthesis byproducts) and quantifies the parent peak as a percentage of the total peptide-related area under the curve. It does not detect non-peptide content — water, salts, residual organic solvents, or endotoxin. A 99.7% HPLC number means 99.7% of the peptide-related material is the parent molecule; it says nothing about the dry-fill or sterility profile, which is why the vial line carries a fuller workup.
Why endotoxin, TFA, and heavy metals on the vial line. The pen line ships pre-formulated and pH-balanced, so the relevant Janoshik panel is HPLC purity of the dissolved peptide. The vial line ships as a lyophilized solid for end-user reconstitution, which makes residual-process panels load-bearing: residual TFA from solid-phase synthesis can interfere with cell-based readouts; heavy metals (As, Cd, Pb, Hg) measured by ICP-MS speak to upstream synthesis and dry-fill; bacterial endotoxin via LAL quantifies lipopolysaccharide fragments that can persist through fill steps and confound in-vitro immune-signalling assays. Publishing all four panels is the documentation-first option in the Remy range — see the HPLC purity guide for more on what each number does and doesn't speak to.
Frequently Asked
How often does Remy publish new lab results?
RETP002 was tested 4 November 2025, and the RET-20-C and RET-20-V batches were tested 21–24 April 2026 ahead of the spring 2026 release.
Where can I find the raw Janoshik PDFs?
/coa/<batch-id>/, one directory per batch. /coa/retp002/ for the 30mg pen, /coa/ret-20-c-2604-001/ for the 20mg pen, /coa/ret-20-v-2604-001/ for the vial line. The /coa/ index lists every published batch.
Why does the vial line carry additional panels?
What is the highest published Remy Retatrutide batch?
RET-20-C-2604-001 at 99.841% HPLC — the Retatrutide 20mg Pen lot tested by Janoshik on 23 April 2026. The full report is at /lab-results/retatrutide-20mg-pen/ and the raw COA at /coa/ret-20-c-2604-001/. The other published batches are within 0.6 percentage points of that number, which is the normal inter-batch variation band for synthetic peptides.